Affimed (AFMD)
(Delayed Data from NSDQ)
$5.03 USD
+0.15 (3.07%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $5.04 +0.01 (0.20%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
AFMD 5.03 +0.15(3.07%)
Will AFMD be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AFMD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AFMD
Wall Street Analysts Believe Affimed N.V. (AFMD) Could Rally 146.73%: Here's is How to Trade
Affimed N.V. (AFMD) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
AFMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Does Affimed N.V. (AFMD) Have the Potential to Rally 263.36% as Wall Street Analysts Expect?
Affimed N.V. (AFMD) Upgraded to Buy: Here's What You Should Know
Seer, Inc. (SEER) Reports Q4 Loss, Tops Revenue Estimates
Other News for AFMD
Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
Biotech Alert: Searches spiking for these stocks today
Affimed price target raised by $4 at Stifel, here's why
Truist Financial Sticks to Its Buy Rating for Affimed (AFMD)
Promising Clinical Trials and Strategic Financial Management Affirm Buy Rating for Affimed